Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$8.00 -4.9%	$7.10	$2.05 ▼ $8.72	$749.90M	-0.46	1.02 million shs	782,249 shs
CYBN Cybin	$7.06 -1.5%	$7.86	$4.81 ▼ $13.88	$169.14M	0.68	316,048 shs	430,344 shs
GYRE Gyre Therapeutics	$8.14 -1.0%	$7.65	$6.11 ▼ $19.00	$791.69M	1.8	79,304 shs	61,069 shs
SANA Sana Biotechnology	$3.33 -2.9%	$3.56	$1.26 ▼ $7.30	$815.68M	1.9	6.28 million shs	6.14 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-4.88%	+4.71%	-5.10%	+65.29%	+275.59%
CYBN Cybin	-1.53%	-5.23%	-6.12%	+5.06%	+1,813.28%
GYRE Gyre Therapeutics	-0.97%	+13.21%	+9.85%	-28.28%	-18.44%
SANA Sana Biotechnology	-2.92%	+11.00%	-23.09%	+90.83%	-29.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	3.5419 of 5 stars	4.5	2.0	2.7	2.5	0.6
CYBN Cybin	2.4564 of 5 stars	3.6	0.0	1.8	0.8	1.3
GYRE Gyre Therapeutics	0.0836 of 5 stars	0.0	1.0	1.7	0.8	0.0
SANA Sana Biotechnology	3.3762 of 5 stars	3.5	3.0	3.1	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$11.75	46.88% Upside
CYBN Cybin	3.25	Buy	$85.00	1,103.97% Upside
GYRE Gyre Therapeutics	3.00	Buy	N/A	N/A
SANA Sana Biotechnology	3.00	Buy	$8.00	140.24% Upside

Current Analyst Ratings Breakdown

Latest CYBN, AMLX, SANA, and GYRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	AMLX Amylyx Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$10.00
7/8/2025	CYBN Cybin	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$73.00 ➝ $70.00
7/3/2025	SANA Sana Biotechnology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
6/24/2025	AMLX Amylyx Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$17.00
6/24/2025	SANA Sana Biotechnology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00
6/17/2025	AMLX Amylyx Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
5/30/2025	AMLX Amylyx Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	8.16	N/A	N/A	$1.88 per share	4.26
CYBN Cybin	N/A	N/A	N/A	N/A	$10.83 per share	N/A
GYRE Gyre Therapeutics	$102.19M	7.67	$0.20 per share	41.62	$1.34 per share	6.07
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.52 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$301.74M	-$2.50	N/A	N/A	N/A	N/A	-82.48%	-70.15%	N/A
CYBN Cybin	-$57.88M	-$4.60	N/A	N/A	N/A	N/A	-37.58%	-36.59%	N/A
GYRE Gyre Therapeutics	$12.09M	$0.01	814.81	∞	N/A	4.08%	7.67%	6.19%	N/A
SANA Sana Biotechnology	-$266.76M	-$1.06	N/A	N/A	N/A	N/A	-91.96%	-43.07%	N/A

Latest CYBN, AMLX, SANA, and GYRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	GYRE Gyre Therapeutics	$0.03	$0.02	-$0.01	$0.04	$30.80 million	$26.77 million
8/11/2025	Q2 2025	SANA Sana Biotechnology	-$0.20	-$0.16	+$0.04	-$0.39	N/A	N/A
8/7/2025	Q2 2025	AMLX Amylyx Pharmaceuticals	-$0.44	-$0.46	-$0.02	-$0.46	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CYBN Cybin	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	8.72	8.72
CYBN Cybin	N/A	24.24	24.24
GYRE Gyre Therapeutics	N/A	5.40	3.19
SANA Sana Biotechnology	N/A	2.47	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
CYBN Cybin	17.94%
GYRE Gyre Therapeutics	23.99%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	12.30%
CYBN Cybin	15.00%
GYRE Gyre Therapeutics	10.00%
SANA Sana Biotechnology	30.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.17 million	78.20 million	Optionable
CYBN Cybin	50	23.59 million	17.96 million	Not Optionable
GYRE Gyre Therapeutics	40	96.31 million	86.68 million	No Data
SANA Sana Biotechnology	380	237.81 million	166.23 million	Optionable

CYBN, AMLX, SANA, and GYRE Headlines

Recent News About These Companies

HC Wainwright Issues Optimistic Forecast for SANA Earnings

1 hour ago | marketbeat.com

Q3 EPS Forecast for Sana Biotechnology Raised by Analyst

August 16 at 3:03 AM | americanbankingnews.com

Sana Biotechnology drops Washington plant build-out, pivots to CDMOs instead

August 14 at 1:29 PM | fiercepharma.comF

Sana Biotechnology Reports Non-Cash Impairment Losses

August 14 at 3:26 AM | theglobeandmail.com

Brokerages Set Sana Biotechnology, Inc. (NASDAQ:SANA) Target Price at $8.00

August 14 at 2:15 AM | americanbankingnews.com

Sana Biotech Bails on Factory in Old AT&T Call Center

August 12, 2025 | finance.yahoo.com

Sana Biotechnology (NASDAQ:SANA) Posts Earnings Results, Beats Estimates By $0.04 EPS

August 12, 2025 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Buy" by Brokerages

August 12, 2025 | marketbeat.com

Sana: Q2 Earnings Snapshot

August 11, 2025 | sfgate.com

Sana suspends build-out of Bothell manufacturing facility

August 11, 2025 | bizjournals.com

Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates

August 11, 2025 | manilatimes.netM

Sana Biotechnology: Fundraising Triggers Major Sell-Off, I'm Still Intrigued

August 8, 2025 | seekingalpha.com

Sana Biotechnology (NASDAQ:SANA) Shares Gap Down - Here's What Happened

August 8, 2025 | marketbeat.com

Seattle biotech firm Sana Biotechnology raising $75 million through public offering

August 8, 2025 | bizjournals.com

Sana Biotechnology stock tumbles after pricing public offering

August 7, 2025 | investing.com

Sana Biotechnology 20.9M share Spot Secondary priced at $3.35

August 7, 2025 | msn.com

Sana Biotechnology Shares Tumble on Pricing of Public Offering

August 7, 2025 | marketwatch.com

Sana Biotechnology (SANA) Projected to Post Earnings on Thursday

August 7, 2025 | marketbeat.com

Sana Biotechnology Announces Pricing of Public Offering

August 6, 2025 | globenewswire.com

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

August 6, 2025 | tmcnet.com

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

August 6, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYBN, AMLX, SANA, and GYRE Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$8.00 -0.41 (-4.88%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$8.11 +0.11 (+1.36%)

As of 08/15/2025 06:50 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Cybin NYSE:CYBN

$7.06 -0.11 (-1.53%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$7.19 +0.13 (+1.86%)

As of 08/15/2025 08:00 PM Eastern

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

Gyre Therapeutics NASDAQ:GYRE

$8.14 -0.08 (-0.97%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$8.11 -0.03 (-0.37%)

As of 08/15/2025 06:45 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Sana Biotechnology NASDAQ:SANA

$3.33 -0.10 (-2.92%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.33 0.00 (-0.03%)

As of 08/15/2025 07:56 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time